A multi-omics recovery factor predicts long COVID in the IMPACC study
Journal of Clinical Investigation, 2025
Gabernet G., Maciuch J., Gygi J., Moore J., Hoch A., Syphurs C., Chu T., Doni Jayavelu N., Corry D., Kheradmand F., Baden L., Sekaly R., McComsey G., Haddad E., Cairns C., Rouphael N., Fernandez-Sesma A., Simon V., Metcalf J., Agudelo Higuita N., Hough C., Messer W., Davis M., Nadeau K., Pulendran B., Kraft M., Bime C., Reed E., Schaenman J., Erle D., Calfee C., Atkinson M., Brakenridge S., Melamed E., Shaw A., Hafler D., Augustine A., Becker P., Ozonoff A., Bosinger S., Eckalbar W., Maecker H., Kim-Schulze S., Steen H., Krammer F., Westendorf K., Network I., Peters B., Fourati S., Altman M., Levy O., Smolen K., Montgomery R., Diray-Arce J., Kleinstein S., Guan L., Ehrlich L.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Infectious Diseases | Patient Stratification | Serum |  Olink Target 96 |
Abstract
Background. Following SARS-CoV-2 infection, ~10-35% of COVID-19 patients experience long COVID (LC), in which debilitating symptoms persist for at least three months. Elucidating biologic underpinnings of LC could identify therapeutic opportunities.
Methods. We utilized machine learning methods on biologic analytes provided over 12-months after hospital discharge from >500 COVID-19 patients in the IMPACC cohort to identify a multi-omics “recovery factor”, trained on patient-reported physical function survey scores. Immune profiling data included PBMC transcriptomics, serum O-link and plasma proteomics, plasma metabolomics, and blood CyTOF protein levels. Recovery factor scores were tested for association with LC, disease severity, clinical parameters, and immune subset frequencies. Enrichment analyses identified biologic pathways associated with recovery factor scores.
Results. LC participants had lower recovery factor scores compared to recovered participants. Recovery factor scores predicted LC as early as hospital admission, irrespective of acute COVID-19 severity. Biologic characterization revealed increased inflammatory mediators, elevated signatures of heme metabolism, and decreased androgenic steroids as predictive and ongoing biomarkers of LC. Lower recovery factor scores were associated with reduced lymphocyte and increased myeloid cell frequencies. The observed signatures are consistent with persistent inflammation driving anemia and stress erythropoiesis as major biologic underpinnings of LC.
Conclusion. The multi-omics recovery factor identifies patients at risk of LC early after SARS-CoV-2 infection and reveals LC biomarkers and potential treatment targets.